BI 836858

DRUG4 trials

Sponsors

Boehringer Ingelheim, Philogen S.p.A.

Conditions

Acute Myeloid Leukemia (AML) RelapseLeukemia, Myeloid, AcuteMyelodysplastic Syndromes

Phase 1

BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse

CompletedNCT01690624

Boehringer IngelheimLeukemia, Myeloid, Acute

Start: 2012-09-13End: 2018-05-21Updated: 2025-01-27

A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)

CompletedNCT02632721

Boehringer IngelheimLeukemia, Myeloid, Acute

Start: 2016-06-16End: 2023-01-16Updated: 2024-03-19

Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

CompletedNCT03207191

Philogen S.p.A.Acute Myeloid Leukemia (AML) Relapse

Start: 2016-12-02End: 2020-03-26Updated: 2022-04-20

Phase 2

Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes

TerminatedNCT02240706

Boehringer IngelheimMyelodysplastic Syndromes

Start: 2015-01-22End: 2019-11-18Updated: 2020-12-21

Related Papers

Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody

Cancers2019-12-0617 citations